Scarlet brings diagnostic service to patients’ homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers ELMWOOD PARK, N.J., January 13, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital platform providing access to on-demand diagnostic […]
Tag Archives: opko
Nearly 210,000 New York City students, teachers, principals and staff were tested by BioReference with a positivity rate of 0.47% ELMWOOD PARK, N.J., (January 4, 2021) – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public schools throughout New York City’s boroughs, with a positivity rate of […]
The Bills leverage testing capabilities from NFL testing provider, BioReference, to initiate fan testing program ORCHARD PARK, N.Y., December 31, 2020 – Buffalo Bills, 2020 AFC East Division Champions, and BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced they will be performing fan testing for the AFC Divisional Wild Card playoff game at […]
New offering identifies COVID-19 and Influenza infections with a single sample ELMWOOD PARK, N.J., October 20, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the […]
Through New York City, BioReference will be testing students, teachers and staff in nearly 1,000 NYC public schools ELMWOOD PARK, N.J., October 9, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school […]
The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today began testing New York City principals, teachers and other staff for COVID-19, across the five boroughs, in preparation for a safer back-to-school environment. Through a […]
ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples. OnkoSight AdvancedNGS testing provides targeted gene content that is aligned with the latest […]
ELMWOOD PARK, N.J., August 18, 2020 – BioReference Laboratories Inc., an OPKO Health Company, is pleased to announce it is now in-network with all Blue Cross and Blue Shield of Texas (BCBSTX) products, including its Health Maintenance Organization (HMO) and Medicaid lines of business. The contract includes BioReference’s subsidiary GeneDx, Inc., a full service genetics […]
GAITHERSBURG, Md., August 12, 2020 – GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), the global leader in neonatal and pediatric genetic testing, announced the entrance into an agreement with Pediatrix Medical Group (“Pediatrix”), the nation’s leading provider of maternal-fetal, and pediatric medical and surgical subspecialty physician services, to offer state-of-the-art, […]
GenomeXpress is a rapid genome sequencing test, reporting results within approximately seven days GAITHERSBURG, Md., Aug. 6, 2020 /PRNewswire/ — GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the launch of GenomeXpress, a rapid genome sequencing test. Verbal GenomeXpress results of pathogenic and/or likely pathogenic variants in known disease causing genes are […]